

1 **Review Article**

2

3 **Potential role of NRF2 agonist in managing AHR-mediated chloracne by dioxin**

4

5 Masutaka Furue^{1,2,3*}, Yoko Fuyuno^{1,2}, Chikage Mitoma^{1,2}, Hiroshi Uchi¹, Gaku Tsuji¹6 ¹Department of Dermatology, Kyushu University, Fukuoka, Japan7 ²Research and Clinical Center for Yusho and Dioxin, Kyushu University, Fukuoka, Japan8 ³Division of Skin Surface Sensing, Kyushu University, Fukuoka, Japan

9

10 *Corresponding author: Masutaka Furue, Department of Dermatology, Kyushu University,

11 Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan

12

13 **Abstract**

14 Chloracne is the major skin symptom caused by dioxin intoxication. Dioxin activates the aryl
15 hydrocarbon receptor (AHR)–cytochrome p450 1A1 (CYP1A1) system, generates oxidative
16 stress, and induces hyperkeratinization of keratinocytes and sebocytes leading to chloracne.17 Nuclear factor-erythroid 2-related factor-2 (NRF2) is a master switch inducing expression of
18 various antioxidative enzymes such as heme oxygenase-1. Cinnamaldehyde is an antioxidant
19 phytochemical that inhibits AHR–CYP1A1 signaling and activates the NRF2–antioxidative axis.20 The cinnamaldehyde-containing Kampo herbal medicine *Keishibukuryogan* is capable of
21 improving chloracne in Yusho patients who are highly contaminated with dioxin. Agents with
22 dual functions in promoting AHR–CYP1A1 inhibition and NRF2 activation may be useful in
23 managing dioxin-related health hazards.

24

25 **Keywords:** Aryl hydrocarbon receptor; Chloracne; Dioxin; Nuclear factor-erythroid 2-related
26 factor-2; heme oxygenase-1; Yusho

27

28 **1. Introduction**

29 Health problems associated with environmental pollutants are an important issue.

30 Environmental polycyclic aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-*p*-dioxin,
31 polychlorinated dibenzofuran, and benzo(a)pyrene (BaP) are high-affinity ligands for aryl
32 hydrocarbon receptor (AHR) or dioxin receptor [1–4]. These chemical compounds strongly
33 activate AHR, generate reactive oxygen species (ROS), and induce the production of
34 inflammatory cytokines in various tissues including skin [1–4]. To maintain cellular
35 homeostasis, excessive production of ROS should be neutralized or minimized by cellular
36 antioxidants including antioxidative enzymes such as heme oxygenase-1 (HMOX1) and

37 NAD(P)H:quinone oxidoreductase 1 (NQO1) [5,6]. The induction of these antioxidative
38 enzymes is upregulated by nuclear factor-erythroid 2-related factor-2 (NRF2), which is a master
39 transcription factor for antioxidant signaling [3,5,6].

40 Exposure to high concentrations of dioxin induces various acute and chronic health hazards
41 including general fatigue, and neurological (numbness or pain in the limbs), respiratory (cough
42 and sputa), and dermatological symptoms [7–9]. In addition, high-dose dioxin intoxication
43 increases the prevalence of cardiovascular diseases, hyperlipidemia, thyroid diseases, diabetes,
44 liver dysfunction, and chronic bronchitis [7,10,11]. Moreover, blood concentrations of dioxins
45 are correlated with some of these conditions such as general fatigue, increased blood sugar, and
46 hyperlipidemia [12]. Increased mortality associated with liver and lung cancers is an additional
47 important issue in dioxin intoxication [13,14].

48 Among the cutaneous symptoms caused by dioxin, chloracne is one of the major ones,
49 causing significant deterioration in the quality of daily life [15–18]. Chloracne has a
50 characteristic skin distribution, with it frequently affecting retroauricular and malar areas of the
51 face, ear lobes, and groin, whereas the nose and perioral area are typically spared [16–20]. The
52 severity of chloracne is also correlated with blood dioxin level [16].

53 The pathology of chloracne is characterized by hyperkeratinization of the interfollicular
54 epidermis, hyperproliferation and hyperkeratinization of hair follicle cells, gradual loss of
55 sebocytes with shrinkage of sebaceous glands, and infundibular dilatation, eventually leading to
56 comedo formation [3,16–18,21,22]. AHR is abundantly expressed in epidermal keratinocytes
57 and sebocytes [3,21]. Moreover, highly lipophilic dioxins appear to accumulate in and are
58 excreted via sebaceous glands and sebum [19,23,24], which facilitates dioxin excretion from the
59 intoxicated body [25]. The high concentration of dioxin in the sebum may explain why
60 chloracne frequently develops in individuals with high-dose dioxin intoxication.

61 In accordance with the histopathology of chloracne, agonistic ligation of AHR accelerates
62 epidermal terminal differentiation and keratinization [26–28]. Upon AHR stimulation, the
63 proliferation and lipid synthesis of sebocytes are impaired, probably by the switching of
64 sebocytes toward keratinocyte-like differentiation [21,29,30]. In this review, we focus on the
65 AHR signaling related to chloracne and highlight its potential treatment using NRF2 agonist.

66

67 **2. AHR signaling in keratinocytes and sebocytes**

68 As a chemical sensor, AHR is constitutively expressed in the tissues separating the inside and
69 outside of the body, including the epidermis and pilosebaceous units [2,3,31]. Dioxins activate
70 AHR and induce its cytoplasmic-to-nuclear translocation. Nuclear AHR binds to its specific
71 DNA recognition site, namely, xenobiotic responsive element, and upregulates the transcription
72 of responsive genes such as cytochrome p450 1A1 (CYP1A1) in keratinocytes and sebocytes

73 [2,3,31]. CYP1A1 is a xenobiotic-metabolizing enzyme and commits to metabolize dioxin [1].
74 As dioxin is very stable and persistent, the metabolizing process by CYP1A1 generates high
75 levels of ROS (Fig. 1). In CYP1A1-deficient conditions, the ROS production is profoundly
76 attenuated [4,32]. The ROS-mediated oxidative stress induces DNA damage and upregulates the
77 production of inflammatory cytokines and chemokines such as IL-8 and CCL2 from
78 keratinocytes [1,4,33].

79 In addition to generating oxidative stress, persistent activation of AHR by dioxin accelerates
80 the terminal differentiation of keratinocytes and epidermal hyperkeratosis [27,28]. This effect is
81 mediated by coordinated upregulation of the gene expression of epidermal terminal
82 differentiation molecules such as filaggrin and proline-rich small proteins (Fig. 1) [26,34].

83 Upon AHR activation by dioxin, sebocytes lose their specific features for sebaceous
84 differentiation including lipogenesis, keratin 7 expression, and epithelial membrane antigen
85 expression [21]. Instead, AHR ligation converts sebocytes towards keratinocytic differentiation,
86 upregulating keratin 10 and peroxisome proliferator-activated receptor- δ [21]. These findings
87 are corroborated by ex vivo sebaceous gland cultures showing that dioxin induces the shrinkage
88 and disappearance of sebaceous glands [21]. These keratinocytic and sebocytic alterations by
89 dioxin coincide with the pathological features of chloracne [18,22].

90

91 **3. Role of NRF2 in neutralizing AHR-mediated oxidative stress**

92 In unstimulated conditions, NRF2 resides in the cytoplasm, but upon activation, it
93 translocates to the nucleus. The antioxidative enzymes downstream of NRF2 include HMOX1,
94 NQO1, glutathione S-transferase, UDP-glucuronosyltransferases, epoxide hydrolase,
95 glutathione reductase, thioredoxin reductase, catalase, and superoxide dismutase. NRF2 also
96 activates the transcription of genes encoding non-enzymatic antioxidative proteins, such as
97 thioredoxin and ferritin [6].

98 Dioxin induces AHR-mediated ROS production [26,35]. The oxidative stress reciprocally
99 activates the NRF2–antioxidative pathway in order to neutralize excessive ROS generation [36].
100 However, persistent activation of the AHR-oxidative pathway by chemically stable dioxin
101 overwhelms the NRF2–antioxidative signaling, leaving the cell in a ROS-rich milieu.

102 A variety of salubrious, antioxidative plants and herbs utilize NRF2 to exert antioxidative
103 activity. For example, phytoextracts from artichoke in Mediterranean countries, cactus *Opuntia*
104 *ficus-indica* in Mexico, and Asian herb *Houttuynia cordata* inhibit the AHR-mediated oxidative
105 stress via NRF2 activation [37–39]. Moreover, NRF2-mediated antioxidative activity is capable
106 of alleviating ROS production induced by tumor necrosis factor- α [37–39]. These results
107 highlight that exogenous NRF2 agonists can antagonize dioxin–AHR–ROS signaling.

108

109 4. Therapeutic potential of *Cinnamomum cassia*-containing Kampo herbal medicine for 110 chloracne

111 As antioxidant phytoextracts are potent inhibitors of AHR-mediated oxidative stress, we have
112 screened phytoextracts that inhibit the AHR–CYP1A1 pathway and activate the NRF2–
113 antioxidative pathway. *Cinnamomum cassia* extract and its major constituent cinnamaldehyde
114 have such dual activity [40]. Both *C. cassia* extract and cinnamaldehyde attenuate the AHR–
115 CYP1A1 axis and inhibit oxidative stress [40]. Many Japanese Kampo herbal medicines contain
116 varying doses of *C. cassia* extract. Among them, *Keishibukuryogan* is the strongest inhibitor of
117 AHR–CYP1A1 signaling [40]. In addition, both *C. cassia* extract and cinnamaldehyde activate
118 the NRF2–HMOX1 antioxidative system and inhibit AHR-mediated ROS production (Fig. 1)
119 [40].

120 We conducted a clinical trial of the oral administration of *Keishibukuryogan* for treating
121 Yusho patients who had been intoxicated with high concentrations of polychlorinated
122 dibenzofurans after they ate a contaminated rice bran oil in 1968 [8,9]. Their mean blood
123 concentration of polychlorinated dibenzofurans still remains more than 10 times higher than that
124 of normal individuals, 30 and 40 years after the accident [41,42]. They suffer from chloracne,
125 general fatigue, numbness and paresthesia of the extremities, cough, and expectoration of
126 sputum [9]. After 3-month oral administration, *Keishibukuryogan* significantly attenuated the
127 symptoms of chloracne, general fatigue, and cough and expectoration of sputum. It also tended
128 to reduce symptoms of numbness and paresthesia of the extremities [9].

129 Perillaldehyde is another useful phytochemical [33]. It is a flavoring ingredient found in
130 *Perilla frutescens* (*shiso* in Japanese), which adds spiciness and a citrus taste to food. Like
131 cinnamaldehyde, perillaldehyde inhibits AHR–CYP1A1 signaling and activates the NRF2–
132 HMOX1 antioxidative axis [33]. Unfortunately, *P. frutescens* extract-containing Kampo
133 medicines do not exhibit similar activities, suggesting that dried *P. frutescens* extract may lose
134 the flavoring perillaldehyde during the extraction process. However, consuming fresh *P.*
135 *frutescens* in meals on a daily basis may be helpful in managing chloracne.

136

137 5. Conclusion

138 Chloracne is a devastating skin symptom induced by exposure to high concentrations of
139 dioxins and other hazardous compounds. These environmental pollutants bind to and activate
140 AHR and generate abundant ROS. They also accelerate the terminal differentiation and
141 keratinization of keratinocytes and sebocytes. As dioxin is stable and resistant to metabolization,
142 persistent activation of AHR results in exaggerated oxidative stress and unopposed
143 hyperkeratinization. These features probably explain the pathogenesis of chloracne.

144 Cinnamaldehyde and perillaldehyde are potent phytochemicals that inhibit the AHR–

145 CYP1A1 pathway and activate the NRF2–antioxidative axis [33,40]. Given that
146 cinnamaldehyde-containing herbal medicine improves the clinical symptoms of patients with
147 dioxin intoxication, agents with dual functions in promoting AHR–CYP1A1 inhibition and
148 NRF2 activation are potential candidates for managing dioxin hazards. Since *C. cassia* and *P.*
149 *frutescens* are inexpensive and popular plants in Asia, their daily ingestion may be a suitable
150 approach for defending against health hazards of people living in areas contaminated with high
151 levels of dioxins.

152

153 **Conflict of interest**

154 The authors declare that they have no conflicts of interest.

155


156 **Acknowledgment**

157 This work was partly supported by a grant (H30-Shokuhin-Shitei-005) for Research on Food
158 Safety from The Ministry of Health, Labour and Welfare, Japan.

159

160

161



162

163 **Legend for figure**

164 Fig. 1

165 Dioxins activate aryl hydrocarbon receptor (AHR), upregulate the expression of cytochrome
 166 P450 1A1 (CYP1A1), and generate reactive oxygen species (ROS) in keratinocytes and
 167 sebocytes. Ligation of AHR by dioxins also accelerates terminal differentiation. Oxidative stress
 168 and hyperkeratinization are probably responsible for chloracne. Cinnamaldehyde (a functional
 169 component of *C. cassia*) and perillaldehyde (a functional component of *P. frutescens*) are potent

170 inhibitors of AHR–CYP1A1 signaling. On the other hand, they activate nuclear factor-erythroid
171 2-related factor-2 (NRF2). NRF2 is a master switch for the cellular antioxidative system. The
172 activation of NRF2 upregulates various antioxidative enzymes such as heme oxygenase-1
173 (HMOX1) and neutralizes ROS. These natural phytochemicals are useful for managing
174 chloracne.

175

176 References

- 177 1. Denison, M.S.; Soshilov, A.A.; He, G.; DeGroot, D.E.; Zhao, B. Exactly the same but
178 different: promiscuity and diversity in the molecular mechanisms of action of the aryl
179 hydrocarbon (dioxin) receptor. *Toxicol. Sci.* **2011**, *124*, 1–22.
- 180 2. Esser, C.; Bargen, I.; Weighardt, H.; Haarmann-Stemmann, T.; Krutmann, J. Functions of
181 the aryl hydrocarbon receptor in the skin. *Semin. Immunopathol.* **2013**, *35*, 677–691.
- 182 3. Furue, M.; Takahara, M.; Nakahara, T.; Uchi, H. Role of AhR/ARNT system in skin
183 homeostasis. *Arch. Dermatol. Res.* **2014**, *306*, 769–779.
- 184 4. Tsuji, G.; Takahara, M.; Uchi, H.; Takeuchi, S.; Mitoma, C.; Moroi, Y.; Furue, M. An
185 environmental contaminant, benzo(a)pyrene, induces oxidative stress-mediated
186 interleukin-8 production in human keratinocytes via the aryl hydrocarbon receptor signaling
187 pathway. *J. Dermatol. Sci.* **2011**, *62*, 42–49.
- 188 5. Furue, M.; Uchi, H.; Mitoma, C.; Hashimoto-Hachiya, A.; Chiba, T.; Ito, T.; Nakahara, T.;
189 Tsuji G. Antioxidants for healthy skin: The emerging role of aryl hydrocarbon receptors and
190 nuclear factor-erythroid 2-related factor-2. *Nutrients* **2017**, *9*, pii: E223.
- 191 6. Gęgotek, A.; Skrzydlewska, E. The role of transcription factor Nrf2 in skin cells metabolism.
192 *Arch. Dermatol. Res.* **2015**, *307*, 385–396.
- 193 7. Akahane, M.; Matsumoto, S.; Kanagawa, Y.; Mitoma, C.; Uchi, H.; Yoshimura, T.; Furue,
194 M.; Imamura, T. Long-term health effects of PCBs and related compounds: A comparative
195 analysis of patients suffering from Yusho and the general population. *Arch. Environ.*
196 *Contam. Toxicol.* **2018**, *74*, 203–217.
- 197 8. Mitoma, C.; Uchi, H.; Tsukimori, K.; Yamada, H.; Akahane, M.; Imamura, T.; Utani, A.;
198 Furue, M. Yusho and its latest findings-A review in studies conducted by the Yusho Group.
199 *Environ. Int.* **2015**, *82*, 41–48.
- 200 9. Mitoma, C.; Uchi, H.; Tsukimori, K.; Todaka, T.; Kajiwara, J.; Shimose, T.; Akahane, M.;
201 Imamura, T.; Furue, M. Current state of yusho and prospects for therapeutic strategies.
202 *Environ. Sci. Pollut. Res. Int.* **2017**, doi: 10.1007/s11356-017-0833-1.
- 203 10. Geusau, A.; Abraham, K.; Geissler, K.; Sator, M.O.; Stingl, G.; Tschachler, E. Severe
204 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: clinical and laboratory effects.
205 *Environ. Health Perspect.* **2001**, *109*, 865–869.

- 206 11. Mohsenzadeh, M.S.; Zanjani, B.R.; Karimi, G. Mechanisms of
207 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cardiovascular toxicity: An overview. *Chem.*
208 *Biol. Interact.* **2018**, *282*, 1–6.
- 209 12. Kanagawa, Y.; Matsumoto, S.; Koike, S.; Tajima, B.; Fukiwake, N.; Shibata, S.; Uchi, H.;
210 Furue, M.; Imamura, T. Association of clinical findings in Yusho patients with serum
211 concentrations of polychlorinated biphenyls, polychlorinated quarterphenyls and
212 2,3,4,7,8-pentachlorodibenzofuran more than 30 years after the poisoning event. *Environ.*
213 *Health* **2008**, *7*, 47.
- 214 13. Onozuka, D.; Yoshimura, T.; Kaneko, S.; Furue, M. Mortality after exposure to
215 polychlorinated biphenyls and polychlorinated dibenzofurans: a 40-year follow-up study of
216 Yusho patients. *Am. J. Epidemiol.* **2009**, *169*, 86–95.
- 217 14. Li, M.C.; Chen, P.C.; Tsai, P.C.; Furue, M.; Onozuka, D.; Hagihara, A.; Uchi, H.; Yoshimura,
218 T.; Guo, Y.L. Mortality after exposure to polychlorinated biphenyls and polychlorinated
219 dibenzofurans: a meta-analysis of two highly exposed cohorts. *Int. J. Cancer* **2015**, *137*,
220 1427–1432.
- 221 15. Caputo, R.; Monti, M.; Ermacora, E.; Carminati, G.; Gelmetti, C.; Gianotti, R.; Gianni, E.;
222 Puccinelli, V. Cutaneous manifestations of tetrachlorodibenzo-p-dioxin in children and
223 adolescents. Follow-up 10 years after the Seveso, Italy, accident. *J. Am. Acad. Dermatol.*
224 **1988**, *19*, 812–819.
- 225 16. Mitoma, C.; Mine, Y.; Utani, A.; Imafuku, S.; Muto, M.; Akimoto, T.; Kanekura, T.; Furue,
226 M.; Uchi, H. Current skin symptoms of Yusho patients exposed to high levels of
227 2,3,4,7,8-pentachlorinated dibenzofuran and polychlorinated biphenyls in 1968.
228 *Chemosphere* **2015**, *137*, 45–51.
- 229 17. Saurat, J.H.; Kaya, G.; Saxer-Sekulic, N.; Pardo, B.; Becker, M.; Fontao, L.; Mottu, F.;
230 Carraux, P.; Pham, X.C.; Barde, C.; Fontao, F.; Zennegg, M.; Schmid, P.; Schaad, O.;
231 Descombes, P.; Sorg, O. The cutaneous lesions of dioxin exposure: lessons from the
232 poisoning of Victor Yushchenko. *Toxicol. Sci.* **2012**, *125*, 310–317.
- 233 18. Suskind, R.R. Chloracne, "the hallmark of dioxin intoxication". *Scand. J. Work Environ.*
234 *Health* **1985**, *11*, 165–171.
- 235 19. Sorg, O.; Zennegg, M.; Schmid, P.; Fedosyuk, R.; Valikhnovskiy, R.; Gaide, O.; Kniazevych,
236 V.; Saurat, J.H. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor
237 Yushchenko: identification and measurement of TCDD metabolites. *Lancet* **2009**, *374*,
238 1179–1185.
- 239 20. Tindall, J.P. Chloracne and chloracnegens. *J. Am. Acad. Dermatol.* **1985**, *13*, 539–558.
- 240 21. Ju, Q.; Fimmel, S.; Hinz, N.; Stahlmann, R.; Xia, L.; Zouboulis, C.C.
241 2,3,7,8-Tetrachlorodibenzo-p-dioxin alters sebaceous gland cell differentiation in vitro. *Exp.*

- 242 *Dermatol.* **2011**, *20*, 320–325.
- 243 22. Panteleyev, A.A.; Bickers, D.R. Dioxin-induced chloracne--reconstructing the cellular and
244 molecular mechanisms of a classic environmental disease. *Exp. Dermatol.* **2006**, *15*, 705–
245 730.
- 246 23. Iida, T.; Hirakawa, H.; Matsueda, T.; Takenaka, S.; Yu, M.L.; Guo, Y.L. Recent trend of
247 polychlorinated dibenzo-p-dioxins and their related compounds in the blood and sebum of
248 Yusho and Yu Cheng patients. *Chemosphere* **1999**, *38*, 981–993.
- 249 24. Morokuma, S.; Tsukimori, K.; Hori, T.; Kato, K.; Furue, M. The vernix caseosa is the main
250 site of dioxin excretion in the human foetus. *Sci. Rep.* **2017**, *7*, 739.
- 251 25. Matsumoto, S.; Akahane, M.; Kanagawa, Y.; Kajiwara, J.; Todaka, T.; Yasukawa, F.; Uchi,
252 H.; Furue, M.; Imamura T. Individuals' half-lives for 2,3,4,7,8-penta-chlorodibenzofuran
253 (PeCDF) in blood: correlation with clinical manifestations and laboratory results in subjects
254 with Yusho. *Chemosphere* **2013**, *92*, 772–777.
- 255 26. Kennedy, L.H.; Sutter, C.H.; Leon Carrion, S.; Tran, Q.T.; Bodreddigari, S.; Kensicki, E.;
256 Mohny, R.P.; Sutter, T.R. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated production of
257 reactive oxygen species is an essential step in the mechanism of action to accelerate human
258 keratinocyte differentiation. *Toxicol. Sci.* **2013**, *132*, 235–249.
- 259 27. Loertscher, J.A.; Sattler, C.A.; Allen-Hoffmann, B.L. 2,3,7,8-Tetrachlorodibenzo-p-dioxin
260 alters the differentiation pattern of human keratinocytes in organotypic culture. *Toxicol.*
261 *Appl. Pharmacol.* **2001**, *175*, 121–129.
- 262 28. Loertscher, J.A.; Lin, T.M.; Peterson, R.E.; Allen-Hoffmann, B.L. In utero exposure to
263 2,3,7,8-tetrachlorodibenzo-p-dioxin causes accelerated terminal differentiation in fetal
264 mouse skin. *Toxicol. Sci.* **2002**, *68*, 465–472.
- 265 29. Hu, T.; Wang, D.; Yu, Q.; Li, L.; Mo, X.; Pan, Z.; Zouboulis, C.C.; Peng, L.; Xia, L.; Ju, Q.
266 Aryl hydrocarbon receptor negatively regulates lipid synthesis and involves in cell
267 differentiation of SZ95 sebocytes in vitro. *Chem. Biol. Interact.* **2016**, *258*, 52–58.
- 268 30. Liu, Q.; Wu, J.; Song, J.; Liang, P.; Zheng, K.; Xiao, G.; Liu, L.; Zouboulis, C.C.; Lei, T.
269 Particulate matter 2.5 regulates lipid synthesis and inflammatory cytokine production in
270 human SZ95 sebocytes. *Int. J. Mol. Med.* **2017**, *40*, 1029–1036.
- 271 31. Stockinger, B.; Di Meglio, P.; Gialitakis, M.; Duarte, J.H. The aryl hydrocarbon receptor:
272 multitasking in the immune system. *Annu. Rev. Immunol.* **2014**, *32*, 403–432.
- 273 32. Anandasadagopan, S.K.; Singh, N.M.; Raza, H.; Bansal, S.; Selvaraj, V.; Singh, S.;
274 Chowdhury, A.R.; Leu, N.A.; Avadhani, N.G. β -Naphthoflavone-induced mitochondrial
275 respiratory damage in *cyp1* knockout mouse and in cell culture systems: Attenuation by
276 resveratrol treatment. *Oxid. Med. Cell Longev.* **2017**, *2017*, 5213186.
- 277 33. Fuyuno, Y.; Uchi, H.; Yasumatsu, M.; Morino-Koga, S.; Tanaka, Y.; Mitoma, C.; Furue, M.

- 278 Perillaldehyde inhibits AHR signaling and activates NRF2 antioxidant pathway in human
279 keratinocytes. *Oxid. Med. Cell Longev.* **2018**, *2018*, 9524657.
- 280 34. Furue, M.; Tsuji, G.; Mitoma, C.; Nakahara, T.; Chiba, T.; Morino-Koga, S.; Uchi, H. Gene
281 regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. *J.*
282 *Dermatol. Sci.* **2015**, *80*, 83–88.
- 283 35. Nie, X.; Liang, L.; Xi, H.; Jiang, S.; Jiang, J.; Tang, C.; Liu, X.; Liu, S.; Wan, C.; Zhao, J.;
284 Yang, J. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces premature senescence of astrocytes
285 via WNT/ β -catenin signaling and ROS production. *J. Appl. Toxicol.* **2015**, *35*, 851–860.
- 286 36. Wang, L.; He, X.; Szklarz, G.D.; Bi, Y.; Rojanasakul, Y.; Ma, Q. The aryl hydrocarbon
287 receptor interacts with nuclear factor erythroid 2-related factor 2 to mediate induction of
288 NAD(P)H:quinoneoxidoreductase 1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Arch. Biochem.*
289 *Biophys.* **2013**, *537*, 31–38.
- 290 37. Doi, K.; Mitoma, C.; Nakahara, T.; Uchi, H.; Hashimoto-Hachiya, A.; Takahara, M.; Tsuji,
291 G.; Nakahara, M.; Furue, M. Antioxidant *Houttuynia cordata* extract upregulates filaggrin
292 expression in an aryl hydrocarbon-dependent manner. *Fukuoka Igaku Zasshi* **2014**, *105*,
293 205–213.
- 294 38. Nakahara, T.; Mitoma, C.; Hashimoto-Hachiya, A.; Takahara, M.; Tsuji, G.; Uchi, H.; Yan,
295 X.; Hachisuka, J.; Chiba, T.; Esaki, H.; Kido-Nakahara, M.; Furue, M. Antioxidant *Opuntia*
296 *ficus-indica* extract activates AHR-NRF2 signaling and upregulates filaggrin and loricrin
297 expression in human keratinocytes. *J. Med. Food* **2015**, *18*, 1143–1149.
- 298 39. Takei, K.; Hashimoto-Hachiya, A.; Takahara, M.; Tsuji, G.; Nakahara, T.; Furue, M.
299 Cynaropicrin attenuates UVB-induced oxidative stress via the AhR-Nrf2-Nqo1 pathway.
300 *Toxicol. Lett.* **2015**, *234*, 74–80.
- 301 40. Uchi, H.; Yasumatsu, M.; Morino-Koga, S.; Mitoma, C.; Furue, M. Inhibition of aryl
302 hydrocarbon receptor signaling and induction of NRF2-mediated antioxidant activity by
303 cinnamaldehyde in human keratinocytes. *J. Dermatol. Sci.* **2017**, *85*, 36–43.
- 304 41. Todaka, T.; Hirakawa, H.; Hori, T.; Tobiishi, K.; Iida, T.; Furue, M. Concentrations of
305 polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and non-ortho and
306 mono-ortho polychlorinated biphenyls in blood of Yusho patients. *Chemosphere* **2007**, *66*,
307 1983–1989.
- 308 42. Todaka, T.; Honda, A.; Imaji, M.; Takao, Y.; Mitoma, C.; Furue, M. Effect of colestimide on
309 the concentrations of polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, and
310 polychlorinated biphenyls in blood of Yusho patients. *Environ. Health* **2016**, *15*, 63.
- 311
- 312